Piper Sandler Maintains Overweight on Arrowhead Pharma, Raises Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Arrowhead Pharma (NASDAQ:ARWR) and raises the price target from $52 to $59.
June 02, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Arrowhead Pharma and raises the price target from $52 to $59.
The news of Piper Sandler maintaining an Overweight rating on Arrowhead Pharma and raising the price target from $52 to $59 indicates a positive outlook for the company. This could lead to an increase in investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100